Sweden· SE-19980805000017
Evista 60 mg Filmdragerad tablett
A medicinal product containing raloxifene hydrochloride, registered in Sweden by Substipharm.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Raloxifene Hydrochloride
- Manufacturer
- Substipharm
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer19980805000017
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Raloxifene hydrochloride in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United Statesraloxifene hydrochlorideGlenmark Pharmaceuticals Inc., USA
- SpainEVISTA 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULASubstipharm
- CzechiaEVISTASubstipharm, Paris
- FranceEVISTA 60 mg, comprimé pelliculéSUBSTIPHARM
- IrelandEvista 60 mg film coated tabletsSubstipharm
- BelgiumOptruma 60 mgEli Lilly Nederland
- FinlandEvistaSubstipharm
- NetherlandsEvista 60 mg, omhulde tablettenSubstipharm
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Austria · Raloxifen Stada
- Cyprus · Ostiral
- Germany · Raloxifen Al, Raloxifen-Hcl Hexal
- Spain · Raloxifeno Aurovitas, Raloxifeno Cinfamed
- France · Raloxifene Arrow, Raloxifene Biogaran
- United Kingdom (Northern Ireland) · Evirex, Ostiral
- Greece · Ostiral
- Hungary · Clastellos, Raloxibone
- Iceland · Evista, Optruma
- Italy · Raloxifene Sandoz
- Liechtenstein · Evista, Optruma
- Netherlands · Raloxifeenhydrochloride Brillpharma, Raloxifene Hydrochloride Aurobindo
- Norway · Evista, Optruma
- Portugal · Raloxifeno Ciclum, Raloxifeno Exeltis
- Romania · Raloxifen Arena
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/05533754-1bb9-41e8-b07a-3f9a19d66708 GET /v1/drugs/05533754-1bb9-41e8-b07a-3f9a19d66708?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EMA",
"EPAR"
],
"se_npl_id": "19980805000017",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=19980805000017",
"product_doc_link": "https://www.ema.europa.eu/en/medicines/human/EPAR/evista"
}See everything about raloxifene hydrochloride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.